Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.05 EUR
Change Today -0.004 / -7.41%
Volume 5.0K
SBH On Other Exchanges
As of 1:36 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

sangui biotech intl inc (SBH) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/10/14 - €0.09
52 Week Low
04/13/15 - €0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANGUI BIOTECH INTL INC (SBH)

Related News

No related news articles were found.

sangui biotech intl inc (SBH) Related Businessweek News

No Related Businessweek News Found

sangui biotech intl inc (SBH) Details

Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. Its artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss. The company also offers nano formulations for the regeneration of skin, including moisturization of the skin and enhanced skin elasticity; offers Chitoskin wound pads for supporting wound healing; Hemospray wound spray, a medical product that is used for the healing of chronic wounds; and cosmetic products. It sells its wound spray product under the Granulox brand name in Europe and Mexico; and cosmetic products through Internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is based in Witten, Germany.

1 Employees
Last Reported Date: 06/25/15
Founded in 1995

sangui biotech intl inc (SBH) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: --
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $37.3K
Compensation as of Fiscal Year 2014.

sangui biotech intl inc (SBH) Key Developments

Sangui Biotech International Inc. Reports Preliminary Unaudited Revenue Results for the Fourth Quarter and Year Ended June 30, 2015

Sangui Biotech International Inc. reported preliminary unaudited revenue results for the fourth quarter and year ended June 30, 2015. Revenues from royalties and product sales were less than $130,000 for fiscal 2015. In fiscal 2014, revenues amounted to $133,470. Revenues in the fourth quarter came in at around $11,000 against $43,729 last year.

Sangui Biotech International Inc. Announces Revenue Results for the Third Quarter and Earnings Results for the Nine Months Ended March 31, 2015

Sangui BioTech International Inc. announced revenue results for the third quarter and earnings results for the nine months ended March 31, 2015. In the third quarter (January through March 2015) revenues amounted to USD 11,654 a decrease of 62.6% as compared with the most recent quarter (October through December 2014). The company reports revenues from product sales and royalties in the amount of USD 116,560, an increase of 29.9% over the revenues in the first nine months of the financial year 2014 when revenues amounted to USD 89,741 (previous period numbers not adjusted for exchange rate changes). The net loss attributable to shareholders of the parent company came to USD 537,282 against USD 1,257,727 a year ago. The cash outflow from operations during the nine months amounted to USD 445,557 against USD 452,192 a year ago.

Sangui Biotech International, Inc. Secures Financial Framework of USD 5 Million over Three Years

Sangui Biotech International Inc. has signed an agreement securing a financial framework of USD 5 million. Under the terms of this agreement, Sangui Biotech International Inc. acquires the right to sell shares to a fund of Southridge LLC, an institutional investor, located in Connecticut and New York in the amount of up to USD 5 million over a period of three years. The dilution of existing shareholders is limited to a maximum of 25 million shares of common stock.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBH:GR €0.05 EUR -0.004

SBH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBH.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.1x
Price/Book 25.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 70.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGUI BIOTECH INTL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at